Andere Kunden interessierten sich auch für
![Preparation & Evaluation of Fexofenadine HCL Lozenges by Jaggery]( "Preparation & Evaluation of Fexofenadine HCL Lozenges by Jaggery")
Preparation & Evaluation of Fexofenadine HCL Lozenges by Jaggery23,99 €![Formulation and Development of Dispersible Tablet and Dry Syrup]( "Formulation and Development of Dispersible Tablet and Dry Syrup")
Formulation and Development of Dispersible Tablet and Dry Syrup40,99 €![Estimation of acebrophylline,fexofenadine hcl and montelukast sodium]( "Estimation of acebrophylline,fexofenadine hcl and montelukast sodium")
Estimation of acebrophylline,fexofenadine hcl and montelukast sodium33,99 €![Design and Development of Cefpodoxime Proxetil Dispersible Tablet]( "Design and Development of Cefpodoxime Proxetil Dispersible Tablet")
Design and Development of Cefpodoxime Proxetil Dispersible Tablet32,99 €![Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet]( "Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet")
Formulation & In-Vitro Evaluation of Tolperisone HCl Buoyant Tablet40,99 €![Formulation and evaluation of Buccal Tablet of Venlafaxine HCl]( "Formulation and evaluation of Buccal Tablet of Venlafaxine HCl")
Formulation and evaluation of Buccal Tablet of Venlafaxine HCl38,99 €![Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet]( "Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet")
Formulation and In-vitro Evaluation of Alfuzosin HCl Floating Tablet40,99 €
The purpose of this research was to formulate tasteless complexes of Fexofenadine Hydrochloride with Kyron-134 and to formulate tasteless complex into fast-Dispersible tablets (FDT) for the treatment of allergic rhinitis & chronic idiopathic urticaria. Drug release from FDT in salivary pH was insufficient to impart bitter taste. Complete drug release was observed at gastric pH. The studies indicate that the formulation was taste masked drug can be formulated in to FDT with view to enhance patient compliance & to obtain faster onset action of the drug which would be advantageous in comparison to the currently available conventional forms. Formulations D-5 was found to be palatable with in vitro disintegration time of 20 s Dissolution studies showed complete release of D-5 within 30 min.